INVESTING IN THE FUTURE OF CANNABIS

Recent News
May 15, 2020

PharmaCielo Ltd. (the "Company" or "PharmaCielo") (TSXV:PCLO) (OTCQX: PCLOF) is pleased to announce today that it has obtained a receipt for the Company's (final) short form prospectus dated May...

May 12, 2020

PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF) is pleased to welcome Dr. Claudia Jiménez (Ph.D.) to its board of directors. As a board member, Dr. Jiménez will also...

View more News

View Investor Presentation

If you have any questions please contact investors@pharmacielo.com

CEO Letter to Shareholders
CEO Letter to Shareholders February 2020
Q4 2019 Financial Information
Why Invest

We’re a dominant, vertically integrated Colombian cannabis company.

Colombia is one of the few global jurisdictions that have the readily scalable production capacity, expertise and legislative framework to sustainably meet global cannabis demand over the mid- and long-term. The country’s ideal growing environment and decades of experience has made it the foremost supplier of other agricultural commodities including coffee, cut flowers and bananas.

PharmaCielo’s management team and Board of Directors have experience scaling global commodity and consumer goods businesses both within Colombia and around the world. Learn more about our team here.


139 hectares (15 Million square feet) of available cultivation capacity1

PharmaCielo received its Colombian manufacturing licence in 2016 and has rapidly become the dominant player in Colombia’s rapidly growing legal cannabis sector. The company is licensed to produce both CBD-dominant and THC-dominant cannabis under quota from the Colombian government. The company was the first Colombian recipient of a licence to cultivate THC-dominant strains and produce THC-focused cannabis oil extracts.

PharmaCielo is on track to rapidly scale its vertically integrated Colombian operations, while expanding operations globally.


2019 commercial-scale production & sale

The company is currently producing CBD-focused cannabis oil extracts. PharmaCielo is completing the construction of its GMP2 certified (Good Manufacturing Practices) oil processing facility and expects to begin commercial-scale production and sale of both CBD-focused and THC-focused cannabis oil extracts in 2020.